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Abstract   
Cefepime, ceftazidime and piperacillin/tazobactam are commonly used beta-lactam 
antibiotics in the critical care setting. For critically ill patients receiving prolonged 
intermittent renal replacement therapy (PIRRT), limited pharmacokinetic data are available to 
inform clinicians on the dosing of these agents. Monte Carlo simulations (MCS) can be used 
to guide drug dosing when pharmacokinetic trials are not feasible. For each antibiotic, MCS 
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to evaluate multiple dosing regimens in 4 different PIRRT effluent rate and PIRRT duration 
combinations (4L/h×10h or 5L/h×8h in hemodialysis and hemofiltration modes). Antibiotic 
regimens were also modeled depending on whether drugs were administered during or well 
before PIRRT therapy commenced. The probability of target attainment (PTA) was 
calculated using each antibiotics’ pharmacodynamic target during the first 48h of therapy. 
Optimal doses were defined as the smallest daily dose achieving ≥90% PTA in all PIRRT 
effluent and duration combinations. Cefepime 1g q6h following a 2g loading dose, 
ceftazidime 2g q12h and piperacillin/tazobactam 4.5g q6h attained the desired 
pharmacodynamic target in ≥90% of modeled PIRRT patients. Alternatively, if a q6h 
cefepime regimen is not desired, the cefepime 2g pre-PIRRT and 3g post-PIRRT regimen 
also met targets. For ceftazidime, 1g q6h or 3g continuous infusion following a 2g loading 
dose also met targets. These recommended doses provide simple regimens that are likely 
achieve the pharmacodynamics target while yielding the least overall drug exposure which 
should result in lower toxicity rates. These findings should be validated in the clinical setting. 
 
Key Words: cefepime, ceftazidime, piperacillin/tazobactam, pharmacokinetics,  Monte Carlo 
simulation, renal replacement therapy 
Introduction   
The primary cause of acute kidney injury (AKI) in critically ill patients is due to 
sepsis. AKI is associated with high mortality rates (>50%)
1
 and often requires treatment with 
renal replacement therapy (RRT). Currently, different types of RRTs are utilized in the 
intensive care units (ICU) including intermittent hemodialysis (IHD), continuous renal 
replacement therapy (CRRT), and hybrids of conventional RRTs that are known by many 
names, including sustained low efficiency dialysis (SLED), extended daily dialysis (EDD), or 
prolonged intermittent renal replacement therapy (PIRRT).
2
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usage due to improved patient mobility compared to CRRT, lower RRT operation cost 
compared to CRRT and better hemodynamic tolerance compared to IHD.
2-6
 Despite the 
advantages of PIRRT, some clinicians are hesitant to use PIRRT due to the lack of 
pharmacokinetic studies (fewer than 1% of drugs have been studied
7
 to support appropriate 
antibiotic dosing regimens).
8, 9
 This is concerning because the 2016 Surviving Sepsis 
Campaign guideline recommends not only antibiotic therapy to be administered as soon as 
possible but also antibiotic dosing strategies to be optimized based on specific drug properties 
in patients with sepsis to improve patient outcomes.
10
 In silico analyses via Monte Carlo 
Simulation (MCS) have been utilized to provide initial dosing guidance to clinicians if 
conducting pharmacokinetic studies is not feasible or when they have not been conducted.
11-
14
 The MCS approach can incorporate the influence of different RRTs and pharmacokinetic 
profiles derived from specific patient populations.  In this case, existing antibiotic 
pharmacokinetic data derived from critically ill patients can be linked with known RRT drug 
clearance characteristics allowing clinical researchers to predict the efficacy/safety of any 
drug dosing and RRT combination. 
Ceftazidime and cefepime are third- and fourth-generation cephalosporins, 
respectively with antimicrobial activity against Gram-positive and Gram-negative bacteria, 
including Pseudomonas aeruginosa.
15, 16
 Piperacillin/tazobactam is a β-lactam/β-lactamase 
inhibitor antibiotic combination product with broad-spectrum antibacterial activity against 
Pseudomonas aeruginosa and CTX-M beta-lactamase producing Enterobacteriaceae.
17
 The 
antibacterial effect of piperacillin/tazobactam is primarily attributable to the activity of 
piperacillin while tazobactam inhibits piperacillin hydrolysis by β-lactamases. Like other 
cephalosporins and β-lactams, ceftazidime, cefepime and piperacillin/tazobactam exhibit 
time-dependent bactericidal activity and their clinical outcome may be predicted by the time 









 Maximum bactericidal activity and suppression of bacterial resistance 
may be achieved when the free drug concentration is at between 1-4 MIC.18 Even though β-
lactam typically has a time-dependent activity, these drugs have shown to exhibit  
concentration-dependent bactericidal activity up to an MIC of 4.
18,19
 We chose 
pharmacodynamics targets to be free concentration at least 50% (piperacillin/tazobactam)
19
 
and 60% (cefepime and ceftazidime)
20
 above 4 MIC of the dosing interval (fT > 4×MIC) to 
maximize bactericidal activity within the first 48 hours. 
18,21-23
 Cefepime therapy has recently 
been associated with neurotoxicity, particularly in patients with renal impairment.
24
 
Numerous case reports have documented cefepime-related neurological toxicity, including 
encephalopathy, confusion, myoclonus, and seizures with coma and death observed in some 
cases.
24-26
 Due to the rising incidence of cefepime-induced toxicity, the US Food and Drug 
Administration released a safety announcement in 2012 to remind clinicians of the need to 
reduce cefepime doses in patients with renal impairment.
27
 Both ceftazidime and piperacillin 
are associated with neurotoxicity.
28
 Currently, there is limited information on dosing 
cefepime, ceftazidime and piperacillin/tazobactam in critically ill patients receiving PIRRT. 
In this study, MCS were performed to formulate cefepime, ceftazidime, and 
piperacillin/tazobactam dosing recommendations for critically ill patients receiving four 
common settings of PIRRT. The objectives of this MCS study were: 1) to determine 
probability of target attainment (PTA) over 48 hours of therapy for many dosing regimens; 
and 2) to predict empiric dosing regimens for listed beta-lactams that are most likely to attain 
the pharmacodynamic target to treat P. aeruginosa infections in critically ill patients 











Mathematical Pharmacokinetic Model 
A one-compartment, first order, and multiple-dose pharmacokinetic model was 
developed to evaluate the effect of PIRRT on the plasma concentration-time profile of 
cefepime, ceftazidime and piperacillin/tazobactam. Table 1 outlines demographic and 
pharmacokinetic parameters that were used in this MCS study. Pharmacokinetic data [volume 
of distribution (Vd), unbound fraction and non-renal clearance (CLNR)] were collected from 
published studies via PubMed searches.
8, 29-52
  
Four different PIRRT settings commonly used in practice were simulated: 8 hours/day 
(ultrafiltration rate/dialysate flow rate of 5L/h) or 10 hours/day (ultrafiltration rate/dialysate 
flow rate of 4L/h) of hemofiltration (HF) or hemodialysis (HD). Ultrafiltrate replacement 
using the pre-dilution technique (all replacement solutions were infused before hemodiafilter) 
was modeled for all HF simulations. The timing of cefepime, ceftazidime and 
piperacillin/tazobactam dose relative to PIRRT was also evaluated at the two possible 
extremes. The first dose administered at the start of PIRRT (T0) or 14 to 16 (T14 and T16) 
hours before the next session of PIRRT (Figure 1A-B). Blood flow rate (Qb) was fixed at 300 
mL/min for all settings. Drug clearance during hemodialysis and hemofiltration modalities of 
PIRRT was estimated using the following equations: 
(Eq. 1) Hemofiltration Clearance 









Where CLHF represents the transmembrane clearance during pre-dilution 
hemofiltration, 
SC represents the sieving coefficient, 
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Qplasma represents the plasma flow rate, 
(Eq. 2) Plasma flow rate  
Q
plasma
   /h    Q
b
   /h     1  hematocrit   
 Where Qb represents the blood flow rate 
(Eq. 3) Hemodialysis Clearance 
       SA   Qd 
 Where CLHD represents the transmembrane clearance during hemodialysis, 
 SA represents the saturation coefficient, 
 Qd represents the dialysate flow rate 
 
Based on published data in different types of renal replacement therapies, regression analysis 
was used to estimate saturation and sieving coefficients for the effluent flow rates used in our 
model.
 
Hematocrit was assumed to be 30% for the plasma flow rate calculation as this is a 
common hematocrit in subjects receiving PIRRT
53
, and the replacement fluid flow rate 
equaled the fluid removal rate during pre-dilution HF (no net fluid loss).  
 
Dosing Simulations 
Many different dosing regimens were simulated in the MCS for cefepime, ceftazidime 
and piperacillin/tazobactam (Table 2). All modeled doses were administered either q6h, q8h, 
q12h, q24h, extended infusion (4-hour), continuous infusion (24-hour), or at the start (pre) 
and end (post) of PIRRT. For continuous infusion (CI) dosing regimens, the loading dose was 
infused over 0.5h followed immediately by the CI dose which was infused at a rate of the CI 
dose/24h. Plasma drug concentration-time profiles were generated by the MCS (Crystal Ball, 
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subjects was embedded within our model by using the mean and standard deviation (SD) of 
the pharmacokinetic parameters (e.g., weight, Vd, free fraction, CLNR, SA/SC) in a log-
Gaussian distribution with preset limits. The weight for all virtual subjects was limited to a 
minimum of 40 kg with no maximum limit. The minimum and maximum values for CLNR 
and Vd were from the published clinical studies. For SA and SC, a variability of 20% was 
assumed with limits set to 0 and 1. Lastly, the reported correlations between body weight and 
Vd or CLNR (Table 1) from each study were incorporated into our MCS. 
 
Pharmacodynamic Targets  
The pharmacodynamic targets in this study were >50% fT>4 MIC (piperacillin)19, 21-
23
, >50% fT threshold tazobactam concentration
54
 and >60% fT>4 MIC (cefepime and 
ceftazidime)
18-21
 for the first 48 hours of antibiotic therapy. Maintaining an even higher free 
drug concentration (e.g., 4×MIC) may be pivotal in critically ill patients to maximize 
bacterial killing and suppress bacterial resistance.
18
 
 Our goal for reaching these targets within the first 48 hours was based on the 
Surviving Sepsis Guidelines which stress rapid administration of appropriate antimicrobial 
therapy. Because we could not assess appropriateness of antibiotic spectrum of activity in 
these virtual patients, we interpreted “rapid” and “appropriate” as dosing antibiotics to reach 
therapeutic pharmacodynamic targets.
10
 These pharmacodynamic targets were chosen as they 
are associated with maximization of bacterial killing and suppression of antibiotic 
resistance
23
 and have been used in other Monte Carlo analyses.
54-56
 The reference organism 
used in this trial was Pseudomonas aeruginosa since this common pathogen is associated 
with increased mortality rates in the ICU and is a common clinical indication for the three 
study antibiotic agents.
57
 Based on Clinical and Laboratory Standards Institute (CLSI), the 









 We used a  tazobactam concentration of 4mg/L as this is the concentration that 
was used for susceptibility testing.
58
 Thus, we evaluated the attainment of pharmacodynamic 
targets of >50% fT>4 MIC of 16mg/L (=64mg/L for piperacillin), >50% fT>4mg/L 
(tazobactam) and >60% fT>4 MIC of 8mg/L (=32mg/L for cefepime and ceftazidime) for 
the first 48 hours of antibiotic therapy to determine the optimal dosing regimen. Commonly, 
%fT>MIC refers to %fT>MIC in a single dosing interval with assumption of a constant drug 
clearance. However, this assumption of a constant drug clearance cannot be applied in our 
patient population since patients have two distinct clearances depending on whether they are 
receiving PIRRT for 8-10 hours each day. To better represent the clinical situation, we 
conducted simulations with PIRRT occurring at the two extremes of time of the day relative 
to the first antibiotic dose for each drug dosing regimen (T0 and T14/T16).  Two PIRRT 
sessions always were performed within the first 48 hours of antibiotic therapy regardless of 
timing relative to antibiotic dose. Ideally the drug infusion would not occur as PIRRT is 
starting, but in clinical practice PIRRT and drug dose timing cannot always be timed 
optimally, hence even the least optimal scenario was simulated.  
 
Optimal Dosing Regimen  
A probability of target attainment (PTA) of 90% is a standard threshold to determine 
the optimal drug dosing regimen in simulation studies.
11, 59
 At that threshold, MCS predicts 
that at least 90% of the virtual patient population will achieve the predetermined 
pharmacodynamic target. The risk of toxicity should be evaluated along with the benefit of 
attaining PTA ≥90%. Focus was placed on cefepime, ceftazidime and piperacillin, drugs with 
a higher risk of toxicity in patients with kidney disease.
28, 60, 61
 Trough cefepime serum 
concentrations >70 mg/L, and ceftazidime serum concentration >100 mg/L have been 
associated with seizures.
60, 61
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who had piperacillin trough serum concentrations >361.4 mg/L.
28
 Keeping trough 
concentrations below these critical values was considered to be preferable to reduce the risks 
of drug-induced neurotoxicity within this MCS.
28, 62-64
 The drug regimen considered to be 
“optimal” was one that achieved a PTA of >90% with the lowest daily dose regardless of 
when PIRRT was initiated relative to the first antibiotic dose while maintaining trough 
concentrations below toxic concentrations in as many virtual patients as possible.  
 
Results  
For all drugs in this study, dosing simulations for the 8 and 10-hour HD models and 8 
and 10-hour HF models yielded similar PTA results, suggesting that PIRRT modality did not 
appreciably influence target attainment (data not shown). Table 2 lists all simulated drug 
regimens and shows all regimens that resulted PTA ≥90% for the first 48 hours with the 
pharmacodynamic target of fT>1 MIC. Considerably fewer antibiotic regimens achieved the 
higher pharmacodynamic target of fT>4 MIC.  
Cefepime doses of >6 grams/day were required to reach 90% PTA. The mean  SD 
percent of the first 48 hours of therapy that the serum concentrations were above fT>4 MIC 
for all 5000 subjects was 89.8±31% and 83.7±31% with a 2g loading dose followed by 1g 
every 6 hours for PIRRT at T0 and T16, respectively. Similarly, in the 5000 patients, 
cefepime 2 g pre-PIRRT and 3g post-PIRRT resulted in 81±33% and 82±30% of the dosing 
interval being above fT>4 MIC when PIRRT was initiated at T0 or T16, respectively in the 
first 48 hours of cefepime therapy. Figure 2 illustrates the PTA during the first 48 hours of 
many different cefepime dosing regimens when 8-hour HD is initiated at T0 (Figure 2A) or at 
T16 (Figure 2B). These figures also show the percent of patients with cefepime trough 
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For ceftazidime, the mean  SD percent of the first 48 hours of therapy that the serum 
concentrations were above fT>4 MIC for all 5000 subjects were 84.6±9.7% (PIRRT 8h-HD 
at T0) and 92.6±11.4% (PIRRT 8h-HD at T16) with a 2g every 12 hours regimen. Moreover, 
ceftazidime1g every 6 hours resulted 83.9±10.8% (PIRRT 8h-HD at T0) and 88±11.7% 
(PIRRT 8h-HD at T16) of the dosing interval being above fT>4 MIC in the first 48 hours of 
therapy. Lastly, a ceftazidime 2g loading dose followed by a 3g continuous infusion resulted 
in 96±11% and 97±9% of the first 48 hours fT>4 MIC when PIRRT was initiated at T0 or 
T16, respectively. Figure 3 illustrates the PTA during the first 48 hours of many different 
ceftazidime dosing regimens when 8-hour HD is initiated at T0 (Figure 3A) or at T16 (Figure 
3B). Figure 3 also shows the percent of patients with ceftazidime trough concentrations 
>100mg/L (a toxicity measure) with each of these regimens. 
Piperacillin 4g every 6 hour infused over 30 minutes remained fT>4×MIC for 
78±22% (PIRRT 8h-HD at T0) and 69±28% (PIRRT 8h-HD at T16) for the first 48 hours of 
therapy in the 5000 virtual patients. Lengthening piperacillin infusion time had a modest 
effect on the percent of time the serum concentration was fT>4×MIC in the first 48 hours. An 
extended infusion (4g every 6 hours over 4 hours) yielded 79±22% and 81±23% fT>4×MIC, 
and continuous infusion (16g every 24 hours) reached 78±22% and 80±24% for PIRRT at T0 
and T16 for the first 48 hours of therapy. Finally, tazobactam PTA was ≥95% regardless of 
when the PIRRT 8-h HD was initiated relative to the initial drug dose for all three tested drug 
dosing regimens (Table 2). Figure 4 illustrates the PTA during the first 48 hours of many 
different piperacillin dosing regimens when 8-hour HD is initiated at T0 (Figure 4A) or at 
T16 (Figure 4B). Figure 4 also shows the percent of patients with piperacillin trough 









In this MCS, common PIRRT settings (4L/h×10h or 5L/h×8h of HD or HF) were used 
to evaluate the effect of different modalities (HD vs. HF), treatment durations, effluent rates, 
and timing of drug administration relative to PIRRT. The PTA showed no differences 
between two modalities and treatment durations. Even though convection usually yields 
higher drug clearances per effluent volume than diffusion, especially for larger solutes, we 
used pre-dilution replacement HF in this study, as is usually done clinically, which caused a 
decrease in clearance due to the dilution factor.  
Conversely, the timing of the drug administration relative to PIRRT had more of an 
effect on toxicity measures than on efficacy PTA. To reflect the clinical setting as much as 
possible, the two possible extremes were modeled in this study. The PTAs were lower (less 
virtual patients reached the pharmacodynamic target) when beta-lactams were administrated 
concomitantly with PIRRT initiation (T0) compared to when PIRRT was started as late as 
possible after the drug dose (T14/T16). For cefepime and ceftazidime, extended and 
continuous infusion dosing provided limited improvements in PTA while consistently 
increasing the trough concentrations (higher risk of drug-related toxicity). Interestingly, when 
both cefepime and ceftazidime were administered at T16 (drug and PIRRT were maximally 
apart) the probability of virtual patients reaching the toxic trough concentration at the 48-hour 
time point drastically decreased while maintaining the high PTA for the pharmacodynamic 
efficacy goals (compare Figure 2A with Figure 2B and Figure 3A with Figure 3B). It is well 
known that the timing of a drug administration relative to PIRRT greatly influences the 
pharmacodynamic target attainment.
65
 However, this study highlights the importance of the 
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We were challenged to develop a single best dosing regimen given the toxicity 
concerns of beta-lactams in renally impaired patients. For cefepime, MCS of the typical doses 
used in normal and CRRT patients (1-2g every 12h) did not meet our 90% PTA goal. 
Increasing the dose to 2g every 8h (the maximum labeled dose for cefepime) produced mean 
modeled trough concentrations that were nearly twice that observed with every 12h dosing, 
raising the concern for potential toxicity. Simulations with pre- and post-PIRRT dosing 
achieved our target PTA of ≥90%, but only when the total daily dose was at least 5g (2g pre-
PIRRT, 3g post-PIRRT). Cefepime 1g every 6h after a 2g loading dose (dose on Day 1 = 5g) 
was the regimen that we modeled with the lowest daily dose that reached our goal. Cefepime 
dosing in critically ill patients has been evaluated in numerous studies. Several of these 
studies have shown that the typical dosing regimens of 1-2g every 12h are unlikely to provide 
adequate exposures for organisms with MICs of 8 mg/L.
52, 66, 67
 Our study supports these 
findings as none of these doses reached the ≥90% PTA threshold. A more frequent dosing 
regimen, such as 1g every 6h we recommend, has not been studied. It has been established 
that extended dosing or continuous infusion of cefepime provides greater likelihood of target 
attainment,
68
 but our study suggests that toxicity may be more likely. 
The ceftazidime dosing regimens that met the target in our simulations are consistent 
with those recommended for CRRT
69
 and are much higher than the dose recommended for 
anuric patients (500 mg every 48 h) or for subjects receiving IHD (1g after each IHD 
treatment).
70
 Since ceftazidime and cefepime pharmacokinetics are similar, similar doses of 
1-2 g every 12h are often advocated for both drugs.
71
 However, our study in PIRRT indicates 
that slightly different doses are necessary to meet our PTA criteria with ceftazidime. 
Cefepime has a higher non-renal clearance rate and RRT clearance rate and consequently 
merits a different dosing strategy. Our finding is consistent with other studies that report 
better target attainment for ceftazidime than cefepime.
52
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colleagues showed PTA of 98% for the pharmacodynamic target of 50% fT≥1 MI  with 1g 
every 8h in 16 critically ill patients receiving PIRRT.
72
 The authors recommended 
ceftazidime 1g every 8h to reach their pharmacodynamic target (50% fT≥1 MI ), and 2g 
every 12h to reach a more aggressive pharmacodynamic target (100% fT≥1 MI ). Even 
though our pharmacodynamic targets for ceftazidime were slightly different from Konig’s 
study  60% fT≥1 MI  for traditional and 60% fT≥4 MI  for aggressive pharmacodynamic 
targets), the dosing recommendations of Konig et al. would reach our pharmacodynamic 
targets in >90% of our virtual patients (Table 2).   
For piperacillin and tazobactam, recommended dosing regimens from previous studies 
in different RRT modalities were evaluated in our study. Recommended 
piperacillin/tazobactam doses for patients receiving other types of RRT include 4.5g every 8h 
for patients receiving CRRT
69
 and 2.25g every 8h to 3.375g every 6h for patients receiving 
SLED.
8
 Our MCS results indicate that those CRRT/SLED piperacillin/tazobactam dosing 
regimens did not meet the 90% PTA threshold of patients receiving PIRRT. Our MCS 
indicate that piperacillin/tazobactam 4.5g every 6h for critically ill patients receiving PIRRT 
is preferable; which is the same dose recommended by the manufacturer to treat patients with 
normal renal function.
73
 Although our recommendation is a relatively high dose, this same 
piperacillin/tazobactam dose (4.5g every 6h) and the same PTA has been assessed in patients 
receiving CRRT with the mean effluent rates of 33-65 ml/min.
74
 This study found that only 
66% of patients receiving the same piperacillin/tazobactam dosing regimen attained the 
therapeutic target in the first 48 hours of therapy. Conversely, a prospective observational 
study concluded 4.5g every 8h was frequently insufficient in critically ill patients receiving 
RRT (n=10).
75
 Only 62% and 57% reached their pharmacodynamic target on Day 1 and Day 
4, respectively.
75
 Our MCS could not evaluate the PTA for both drugs simultaneously in the 
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in different sets of 5,000 virtual patients. We found that piperacillin 4g every 6h attains the 
therapeutic target in ~90% of simulated 5,000 patients and tazobactam 0.5g also achieves the 
efficacy target in >90% of another 5,000 virtual patients. Piperacillin/tazobactam have been 
frequently evaluated for alternate dosing strategies in critically ill patients who often require 
higher MIC targets due to their increased risk of bacterial resistance.
42, 63, 76-79
 These studies 
investigated whether prolonging infusion time increases fT>MIC and consequently improves 
patient outcomes. Recent meta-analysis, including data from 632 randomized patients, 
showed continuous piperacillin/tazobactam infusion was associated with decreased hospital 
mortality compared to intermittent infusion  ≤ 30min infusion) in critically ill patients with 
severe sepsis.
80
 Thus, we included 4-hour EI piperacillin/tazobactam and CI regimens with or 
without a loading dose to evaluate if these alternative dosing strategies would result in better 
target attainment than a conventional intermittent infusion. Our study found that prolonging 
piperacillin/tazobactam infusions did not yield significantly better target attainment in 
patients receiving PIRRT.  
This study has several limitations including that our model assumed that all virtual 
patients had a negligible renal clearance. Patients with acute kidney injury have the potential 
for renal recovery. Obviously, if patients had residual renal function or recovered renal 
function, then higher antibiotics doses would be necessary. Also, our recommendations are 
only applicable to patients who receive daily PIRRT at the modeled flow rates. In scenarios 
where PIRRT is not administered daily or if different blood and effluent rates were used, 
dosing adjustments would be necessary. For drugs like aminoglycosides or vancomycin, 
therapeutic drug monitoring (TDM) can be used to guide drug dosing. Beta-lactam TDM 
would be a very helpful tool in this setting 
81, 82
 but is unavailable at most hospitals, 
consequently MCS like the ones conducted here are the best available option to obtain good 
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served as the basis for this MCS came from a sole American center, 
29
 the population was 
quite large (n=100) and likely is representative of the types of patients that would receive 
PIRRT and these antibiotics.  
Lastly, these drug dosing recommendations are based on the target of ~90% of 
critically ill patients receiving PIRRT will attain the pharmacodynamic target. this means that 
up to 10% of patients might not meet the goal. Selected patient populations might be 
responsible for this 10%.  For example, increased weight has been described as a factor for 
inadequate therapy for several studies.
83-85
 Rich et al found that cefepime doses of 2g every 
8h are necessary to maintain an adequate fT>MIC throughout the dosing interval for 
morbidly obese patients (body mass index >40 kg/m
2
) with estimated glomerular filtration 
rate of 108.4±34.6mL/min.
84
 Even though their patients did not have renal dysfunction nor 
receiving renal replacement therapy, their dose recommendation is still vastly different than 
conventional dose of 1-2g every 12h for patients. Our MCS model was not able to calculate 
BMI, however a post-hoc analysis of our virtual patients that were >120 kg indicates that our 
recommended doses for cefepime 2g LD, 1g q6h, ceftazidime 2g q12h, and 
piperacillin/tazobactam 4.5g q6h all had 100% PTA at the 1X MIC threshold no matter when 
the dose was administered relative to PIRRT.   
The dose recommendations from our MCS were based on the susceptibility 
breakpoint of P. aeruginosa established by the Clinical and Laboratory Standards Institute 
(CLSI) for drugs.
58
 In some respects the recommended doses should be more than sufficient 
for organisms that are more sensitive that the breakpoints used in the study.  Similarly, 
organisms that are more resistant and have higher breakpoints should not be receiving these 










In a pharmacokinetic model of critically ill patients receiving 8 hours (5L/h) or 10 
hours (4L/h) of daily PIRRT, cefepime 1g every 6h with a 2g loading dose, ceftazidime 2g 
every12h and piperacillin/tazobactam 4g every 6h will reach the pharmacodynamic targets 
for P. aeruginosa.  While administering drugs during a PIRRT session is not ideal, delaying 
antibiotic therapy cannot be condoned and use of these doses appears to meet the 90% PTA 
threshold for the first 48 hours regardless of when the dose is given relative to PIRRT. A 
validation study in the clinical setting is warranted. 
References 
1. Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill 
patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2(3): 
431-439. 
2. Edrees F, Li T, Vijayan A. Prolonged intermittent renal replacement therapy. Adv 
Chronic Kidney Dis. 2016;23(3): 195-202. 
3. Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: A new approach 
to renal replacement for acute renal failure in the intensive care unit. Am J Kidney 
Dis. 2000;36(2): 294-300. 
4. Bellomo R, Baldwin I, Fealy N. Prolonged intermittent renal replacement therapy in 
the intensive care unit. Crit Care Resusc. 2002;4(4): 281-290. 
5. Marshall MR, Creamer JM, Foster M, et al. Mortality rate comparison after switching 
from continuous to prolonged intermittent renal replacement for acute kidney injury 
in three intensive care units from different countries. Nephrol Dial Transplant. 
2011;26(7): 2169-2175. 
6. Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R. Extended daily 
dialysis versus continuous renal replacement therapy for acute kidney injury: A meta-
analysis. Am J Kidney Dis. 2015;66(2): 322-330. 
7. Roberts JA, Mehta RL, Lipman J. Sustained low efficiency dialysis allows rational 
renal replacement therapy, but does it allow rational drug dosing? Crit Care Med. 
2011;39(3): 602-603. 
8. Harris LE, Reaves AB, Krauss AG, Griner J, Hudson JQ. Evaluation of antibiotic 
prescribing patterns in patients receiving sustained low-efficiency dialysis: 
opportunities for pharmacists. Int J Pharm Pract. 2013;21(1): 55-61. 
9. Mei JP, Ali-Moghaddam A, Mueller BA. Survey of pharmacists' antibiotic dosing 
recommendations for sustained low-efficiency dialysis. Int J Clin Pharm. 2016;38(1): 
127-134. 
10. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International 





This article is protected by copyright. All rights reserved. 
17 
 
11. Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine 
optimal carbapenem dosing in critically ill patients receiving prolonged intermittent 
renal replacement therapy. J Clin Pharmacol. 2016;56(10): 1277-1287. 
12. Gharibian KN, Mueller BA. Fluconazole dosing predictions in critically-ill patients 
receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation 
approach. Clin Nephrol. 2016;86(7): 43-50. 
13. Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing 
antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J 
Antimicrob Chemother. 2011;66(2): 227-231. 
14. Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, 
pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose 
to treat an infection. Pediatr Infect Dis J. 2010;29(11): 1043-1046. 
15. Cheatham SC, Shea KM, Healy DP, et al. Steady-state pharmacokinetics and 
pharmacodynamics of cefepime administered by prolonged infusion in hospitalised 
patients. Int J Antimicrob Agents. 2011;37(1): 46-50. 
16. Jones RN, Barry AL, Thornsberry C, et al. Ceftazidime, a pseudomonas-active 
cephalosporin: in-vitro antimicrobial activity evaluation including recommendations 
for disc diffusion susceptibility tests. J Antimicrob Chemother. 1981;8 Suppl B: 187-
211. 
17. Lodise TP, Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas 
aeruginosa infection: clinical implications of an extended-infusion dosing strategy. 
Clin Infect Dis. 2007;44(3): 357-363. 
18. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. 
Nat Rev Microbiol. 2004;2(4): 289-300. 
19. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial 
dosing of mice and men. Clin Infect Dis. 1998;26(1): 1-10; quiz 11-12. 
20. Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases P. 
Application of antimicrobial pharmacodynamic concepts into clinical practice: focus 
on beta-lactam antibiotics: insights from the Society of Infectious Diseases 
Pharmacists. Pharmacotherapy. 2006;26(9): 1320-1332. 
21. Vitrat V, Hautefeuille S, Janssen C, Bougon D, Sirodot M, Pagani L. Optimizing 
antimicrobial therapy in critically ill patients. Infect Drug Resist. 2014;7: 261-271. 
22. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr. 1986;108(5 Pt 
2): 835-840. 
23. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J 
Infect Dis Suppl. 1990;74: 63-70. 
24. Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and 
neurological toxicity in febrile neutropenic patients with mild impairment of renal 
function. Antimicrob Agents Chemother. 2010;54(10): 4360-4367. 
25. Barbey F, Bugnon D, Wauters JP. Severe neurotoxicity of cefepime in uremic 
patients. Ann Intern Med. 2001;135(11): 1011. 
26. Chatellier D, Jourdain M, Mangalaboyi J, et al. Cefepime-induced neurotoxicity: an 
underestimated complication of antibiotherapy in patients with acute renal failure. 
Intensive Care Med. 2002;28(2): 214-217. 
27. Administration USFD. FDA Drug Safety Communication: Cefepime and risk of 
seizure in patients not receiving dosage adjustments for kidney impairment. Available 




This article is protected by copyright. All rights reserved. 
18 
 
28. Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: 
a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob 
Chemother. 2017;72(10): 2891-2897. 
29. Gashti CN, Salcedo S, Robinson V, Rodby RA. Accelerated venovenous 
hemofiltration: early technical and clinical experience. Am J Kidney Dis. 2008;51(5): 
804-810. 
30. Allaouchiche B, Breilh D, Jaumain H, Gaillard B, Renard S, Saux MC. 
Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. 
Antimicrob Agents Chemother. 1997;41(11): 2424-2427. 
31. Isla A, Gascon AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and 
continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT 
membranes and pharmacokinetics in four critically ill patients. Clin Ther. 2005;27(5): 
599-608. 
32. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime 
during continuous renal replacement therapy in critically ill patients. Antimicrob 
Agents Chemother. 2001;45(11): 3148-3155. 
33. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. 
Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol 
Ther. 1990;48(3): 268-276. 
34. Cronqvist J, Nilsson-Ehle I, Oqvist B, Norrby SR. Pharmacokinetics of cefepime 
dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents 
Chemother. 1992;36(12): 2676-2680. 
35. Schmaldienst S, Traunmuller F, Burgmann H, et al. Multiple-dose pharmacokinetics 
of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin 
Pharmacol. 2000;56(1): 61-64. 
36. Wilson FP, Bachhuber MA, Caroff D, Adler R, Fish D, Berns J. Low cefepime 
concentrations during high blood and dialysate flow continuous venovenous 
hemodialysis. Antimicrob Agents Chemother. 2012;56(4): 2178-2180. 
37. Maynor LM, Carl DE, Matzke GR, et al. An in vivo-in vitro study of cefepime and 
cefazolin dialytic clearance during high-flux hemodialysis. Pharmacotherapy. 
2008;28(8): 977-983. 
38. Kinowski JM, de la Coussaye JE, Bressolle F, et al. Multiple-dose pharmacokinetics 
of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure 
during intermittent hemofiltration. Antimicrob Agents Chemother. 1993;37(3): 464-
473. 
39. Vincent HH, Vos MC, Akcahuseyin E, Goessens WH, van Duyl WA, Schalekamp 
MA. Drug clearance by continuous haemodiafiltration. Analysis of sieving 
coefficients and mass transfer coefficients of diffusion. Blood Purif. 1993;11(2): 99-
107. 
40. Vos MC VH, Yzerman EPF, Vogel M, Mouton JW. Drug clearance by continuous 
haemodiafiltration. Drug Investigation. 1994;7(6): 315-322. 
41. Traunmuller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, 
Thalhammer F. Clearance of ceftazidime during continuous venovenous 
haemofiltration in critically ill patients. J Antimicrob Chemother. 2002;49(1): 129-
134. 
42. Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill 
patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic 




This article is protected by copyright. All rights reserved. 
19 
 
43. Isla A, Gascon AR, Maynar J, Arzuaga A, Sanchez-Izquierdo JA, Pedraz JL. In vitro 
AN69 and polysulphone membrane permeability to ceftazidime and in vivo 
pharmacokinetics during continuous renal replacement therapies. Chemotherapy. 
2007;53(3): 194-201. 
44. Joos B, Schmidli M, Keusch G. Pharmacokinetics of antimicrobial agents in anuric 
patients during continuous venovenous haemofiltration. Nephrol Dial Transplant. 
1996;11(8): 1582-1585. 
45. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance 
by continuous venovenous hemofiltration and continuous venovenous hemodialysis. 
Antimicrob Agents Chemother. 2000;44(6): 1639-1644. 
46. Ohkawa M, Nakashima T, Shoda R, et al. Pharmacokinetics of ceftazidime in patients 
with renal insufficiency and in those undergoing hemodialysis. Chemotherapy. 
1985;31(6): 410-416. 
47. Nikolaidis P, Tourkantonis A. Effect of hemodialysis on ceftazidime 
pharmacokinetics. Clin Nephrol. 1985;24(3): 142-146. 
48. Mueller SC, Majcher-Peszynska J, Hickstein H, et al. Pharmacokinetics of 
piperacillin-tazobactam in anuric intensive care patients during continuous 
venovenous hemodialysis. Antimicrob Agents Chemother. 2002;46(5): 1557-1560. 
49. Arzuaga A, Maynar J, Gascon AR, et al. Influence of renal function on the 
pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during 
continuous venovenous hemofiltration. J Clin Pharmacol. 2005;45(2): 168-176. 
50. Bauer SR, Salem C, Connor MJ, Jr., et al. Pharmacokinetics and pharmacodynamics 
of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am 
Soc Nephrol. 2012;7(3): 452-457. 
51. Keller E, Bohler J, Busse-Grawitz A, Reetze-Bonorden P, Krumme B, Schollmeyer P. 
Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in 
intensive care patients. Clin Nephrol. 1995;43 Suppl 1: S20-23. 
52. Seyler L, Cotton F, Taccone FS, et al. Recommended beta-lactam regimens are 
inadequate in septic patients treated with continuous renal replacement therapy. Crit 
Care. 2011;15(3): R137. 
53. Gashti CN, Rodby RA, Huang Z, Gao D, Zhang W. Effects of high blood flow and 
high pre-dilution replacement fluid rates on small solute clearances in hemofiltration. 
Blood Purif. 2011;32(4): 266-270. 
54. Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage 
adjustments for high-dose extended-infusion cefepime dosing regimens in 
hospitalized patients. J Antimicrob Chemother. 2015;70(3): 877-881. 
55. Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h 
infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte 
Carlo simulation. Diagn Microbiol Infect Dis. 2010;68(3): 251-258. 
56. Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, 
Wongpoowarak W. Pharmacodynamics of meropenem in critically ill patients with 
febrile neutropenia and bacteraemia. Int J Antimicrob Agents. 2011;38(3): 231-236. 
57. Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on 
outcomes in the intensive care unit. Crit Care Med. 2009;37(4): 1463-1469. 
58. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial 
susceptibility testing; 26th Edition. CLSI document M100S. Wayne PC. 
59. Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic 
monotherapies for an intensive care unit (ICU) population based on Canadian 




This article is protected by copyright. All rights reserved. 
20 
 
60. Thurmann-Nielsen E, Walstad RA, Dahl K, Hellum KB. Ceftazidime in patients with 
impaired renal function. Studies on pharmacokinetics and nephrotoxicity. J 
Chemother. 1989;1(4 Suppl): 534-535. 
61. Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic 
considerations, and literature review. Pharmacotherapy. 2006;26(8): 1169-1174. 
62. Smith NL, Freebairn RC, Park MA, Wallis SC, Roberts JA, Lipman J. Therapeutic 
drug monitoring when using cefepime in continuous renal replacement therapy: 
seizures associated with cefepime. Crit Care Resusc. 2012;14(4): 312-315. 
63. Moriyama B, Henning SA, Neuhauser MM, Danner RL, Walsh TJ. Continuous-
infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the 
treatment of resistant gram-negative bacteria. Ann Pharmacother. 2009;43(7): 1324-
1337. 
64. Georges B, Conil JM, Ruiz S, et al. Ceftazidime dosage regimen in intensive care unit 
patients: from a population pharmacokinetic approach to clinical practice via Monte 
Carlo simulations. Br J Clin Pharmacol. 2012;73(4): 588-596. 
65. Scoville BA, Mueller BA. Medication dosing in critically ill patients with acute 
kidney injury treated with renal replacement therapy. Am J Kidney Dis. 2013;61(3): 
490-500. 
66. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and 
pharmacodynamics of cefepime in patients with various degrees of renal function. 
Antimicrob Agents Chemother. 2003;47(6): 1853-1861. 
67. Bhat SV, Peleg AY, Lodise TP, Jr., et al. Failure of current cefepime breakpoints to 
predict clinical outcomes of bacteremia caused by gram-negative organisms. 
Antimicrob Agents Chemother. 2007;51(12): 4390-4395. 
68. Burgess SV, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes of alternative 
dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother. 
2015;49(3): 311-322. 
69. Aronoff GR BW, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer 
WE. Drug prescribing in renal failure: Dosing guidelines for adults and children. 5th 
ed. ed. Philadelphia, PA: American College of Physicians; 2007. 
70. Ceptaz (R) [package insert]. Research Triangle Park NG. 
71. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in 
critically ill adult patients receiving continuous renal replacement therapy. Clin Infect 
Dis. 2005;41(8): 1159-1166. 
72. Konig C, Braune S, Roberts JA, et al. Population pharmacokinetics and dosing 
simulations of ceftazidime in critically ill patients receiving sustained low-efficiency 
dialysis. J Antimicrob Chemother. 2017;72(5): 1433-1440. 
73. Zosyn® (piperacillin & tazobactam) [pkg insert]. Philadelphia PP, Inc.; 2012. 
74. Asin-Prieto E, Rodriguez-Gascon A, Troconiz IF, et al. Population pharmacokinetics 
of piperacillin and tazobactam in critically ill patients undergoing continuous renal 
replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. J 
Antimicrob Chemother. 2014;69(1): 180-189. 
75. Zander J, Dobbeler G, Nagel D, et al. Piperacillin concentration in relation to 
therapeutic range in critically ill patients--a prospective observational study. Crit 
Care. 2016;20: 79. 
76. Langgartner J, Vasold A, Gluck T, Reng M, Kees F. Pharmacokinetics of meropenem 
during intermittent and continuous intravenous application in patients treated by 




This article is protected by copyright. All rights reserved. 
21 
 
77. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or 
continuous versus short-term intravenous infusion of carbapenems and 
piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 
2013;56(2): 272-282. 
78. Yusuf E, Spapen H, Pierard D. Prolonged vs intermittent infusion of 
piperacillin/tazobactam in critically ill patients: a narrative and systematic review. J 
Crit Care. 2014;29(6): 1089-1095. 
79. Yang H, Zhang C, Zhou Q, Wang Y, Chen L. Clinical outcomes with alternative 
dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. 
PLoS One. 2015;10(1): e0116769. 
80. Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent beta-
lactam infusion in severe sepsis. A meta-analysis of individual patient data from 
randomized trials. Am J Respir Crit Care Med. 2016;194(6): 681-691. 
81. Jager NG, van Hest RM, Lipman J, Taccone FS, Roberts JA. Therapeutic drug 
monitoring of anti-infective agents in critically ill patients. Expert Rev Clin 
Pharmacol. 2016;9(7): 961-979. 
82. Cotta MO, Roberts JA, Lipman J. We need to optimize piperacillin-tazobactam 
dosing in critically ill patients-but how? Crit Care. 2016;20(1): 163. 
83. Hites M, Taccone FS, Wolff F, et al. Broad-spectrum beta-lactams in obese non-
critically ill patients. Nutr Diabetes. 2014;4: e119. 
84. Rich BS, Keel R, Ho VP, et al. Cefepime dosing in the morbidly obese patient 
population. Obes Surg. 2012;22(3): 465-471. 
85. Roe JL, Fuentes JM, Mullins ME. Underdosing of common antibiotics for obese 
patients in the ED. Am J Emerg Med. 2012;30(7): 1212-1214. 
 
 
Table 1. Demographic and Pharmacokinetic Parameters Used in Monte Carlo Simulations 
 Cefepime Ceftazidime Piperacillin Tazobactam 
Weight (kg) 
86.6 ± 29.2kg 
 ≥40kg 
29 














































(0 - 1) 
CLNR  (mL/min) 








(8 – 37.7) 
48.5 ± 37
8, 29, 49, 50
 







Sieving coefficient 0.86 ± 0.15 (0 - 
1) 
0.66 ± 0.13 (0 - 
1) 
0.5 ± 0.3 (0 - 1) 0.76 ± 0.26  
(0 - 1) 
Saturation 
coefficient 
0.52 ± 0.10  
(Qef 4L/h) 
0.45 ± 0.08  
(Qef 5L/h) 
0.43 ± 0.09  
(Qef 4L/h) 
0.36 ± 0.07  
(Qef 5L/h) 
0.6 ± 0.28 (0 - 1) 0.8 ± 0.36 (0 - 1) 
Hemofiltration 
clearance 
34.7 (Qef 4L/h) 
37.5 (Qef 5L/h)
31, 
33.4 (Qef 4L/h) 
39.4 (Qef 5L/h)
38, 






















46.4 (Qef 4L/h) 
54.6  
(Qef  5L/h)
31, 32, 36, 
37
 
























0.038 0.1254 0.036 0.0098 
CLNR = Nonrenal clearance; Vd = Volume of distribution; Qef = Effluent rate 
All values are mean ± SD (minimum-maximum limits).  
 
Table 2. Dosing Regimens Simulated for Cefepime, Ceftazidime, Piperacillin and 
Tazobactam. 
Administration Strategies 
Frequency Cefepime  Ceftazidime  Piperacillin  Tazobactam 
Q6H 
1 g 
2 g LD, 1 g
 










2 g EI 
3 g 




0.375 g EI 
0.5 g 
0.5 g EI 
Q8H 
1 g 




















1 g EI 
2 g 
2 g EI 
3 g LD, 2 g 














(Pre) and End 
(Post) of 
PIRRT 
2 g Pre, 2 g Post 
2 g Pre, 3 g Post 
3 g Pre, 2 g Post 
3g LD, 2g Pre, 2g Post 
 
2 g Pre, 1 g Post 







2 g LD, 4 g CI
*
 
2 g LD, 3 g CI 12 g CI 
16 g CI 
 
1.5 g CI 
2 g CI 
CI – continuous infusion (over 24 hours); EI - extended infusion (over 4 hours); LD - loading dose; N/A 
– not available; PIRRT – prolonged intermittent renal replacement therapy
  
*
 depending on when drug is infused relative to PIRRT often results in mean cefepime trough 




 depending on when drug is infused relative to PIRRT often results in mean ceftazidime trough 
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Note: All listed dosing regimens represent probability of target attainment  PTA  ≥90% at 1 minimum 
inhibitory concentration  MI   for the first 48 hours. Underlined dosing regimens represent PTA ≥90% 






Figure 1A. PIRRT initiated at the beginning of the antibiotic therapy (T0) for 8-hour 
and 10-hour hemofiltration or hemodialysis 
Day 1      Day2  
 
 
T0= The initiation of antibiotic therapy 
 
Figure 1B. PIRRT initiated 14 hours after the first antibiotic dose (T14 with 10-hour/ 
T16 with 8-hour) hemofiltration or hemodialysis 
Day 1         Day2  
 
 
T0= The initiation of antibiotic therapy 
 
PIRRT PIRRT 
T0               T24                 T48   
   
PIRRT PIRRT 













Figure 2A: Probability of target attainments when an 8-hour hemodialysis was initiated at 






















































































































































Cefepime dosing regimens 















Figure 2B Probability of target attainments when the first cefepime dose was administered 





Legend for Figures 2A and 2B: 
Abbreviations: 1 MIC = one times minimum inhibitory concentration; 4 MIC = four times 
minimum inhibitory concentration; CI = continuous infusion over 24 hours; EI = extended 
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The pharmacodynamic target for cefepime is determined by the time of the free serum 
concentration above the MIC over 60% of the first 48 hours of cefepime therapy. The PTA 
for 1X MIC (triangles) and 4X MIC (circles) for the first 48 hours of antibiotic therapy are 
illustrated. The percent of virtual patients who attained trough cefepime concentrations of 












Figure 3A: Probability of target attainments when an 8-hour hemodialysis was initiated at 
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Figure 3B: Probability of target attainments when the first ceftazidime dose was 
administered 16 hours (T16) before the next session of 8-hour hemodialysis for a series of 
ceftazidime dosing regimens. 
  
Legend for Figures 3A and 3B: 
Abbreviations: 1 MIC = one times minimum inhibitory concentration; 4 MIC = four times 
minimum inhibitory concentration; CI = continuous infusion over 24 hours; EI = extended 
infusion over 4 hours; LD = loading dose; MIC = minimum inhibitory concentration; q = 
every 
The pharmacodynamic target for ceftazidime is determined by the time of the free 
serum concentration above the MIC over 60% of the first 48 hours of ceftazidime therapy. 
The PTA for 1X MIC (triangles) and 4X MIC (circles) for the first 48 hours of antibiotic 
therapy are illustrated.  The percent of virtual patients who attained trough ceftazidime 
concentrations of >100 mg/L, which may be associated with neurotoxicity, with each regimen 
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Figure 4A: Probability of target attainments when an 8-hour hemodialysis was initiated at 





























































































































Piperacillin dosing regimens 
8-H Hemodialysis at T0 
PTA (0-48h) at 4XMIC
Trough >361.4mg/L
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Figure 4B: Probability of target attainments when the first piperacillin dose was administered 




Legend for Figures 4A and 4B: 
Abbreviations: 1 MIC = one times minimum inhibitory concentration; 4 MIC = four times 
minimum inhibitory concentration; CI = continuous infusion over 24 hours; EI = extended 
infusion over 4 hours; LD = loading dose; MIC = minimum inhibitory concentration; q = 
every 
The pharmacodynamic target for piperacillin is determined by the time of the free 
serum concentration above the MIC over 50% of the first 48 hours of piperacillin therapy. 


















































































































Piperacillin dosing regimens 
8-H Hemodialysis at T16 
PTA (0-48h) at 1XMIC
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therapy are illustrated.  The 50% of virtual patients who attained trough piperacillin 
concentrations of >361.4 mg/L, is associated with neurotoxicity, with each regimen are 
shown with squares.  
 
 
 
